Rapport Therapeutics

Historical price data

Rapport Therapeutics is advancing a new class of precision medicines for brain disorders by targeting specific receptor-associated proteins (RAPs) to achieve unprecedented selectivity and therapeutic windows. The company's lead candidate, RAP-219, is a GABA-A receptor-associated protein modulator in Phase 1b/2a development for drug-resistant focal epilepsy, with a broader pipeline targeting other neurological conditions. Founded by industry veterans and backed by a strong syndicate, Rapport leverages deep neuroscience expertise to address high-unmet-need disorders with its innovative platform.

A precision neuroscience platform developing small molecule modulators that target specific receptor-associated proteins (RAPs) to achieve circuit-selective therapeutic effects for neurological and psychiatric disorders.

3 drugs in pipeline

Total raised: $523.5M

Rapport's main competitors are large pharma and biotechs developing novel therapies for epilepsy and anxiety (e.g., Marinus, Neurocrine, Biogen). Rapport differentiates itself through its unique RAP-targeting platform, which aims to achieve circuit-specific modulation of key receptors, potentially offering superior efficacy and tolerability compared to broad-acting standard-of-care drugs.